Data presented at ESC Congress 2021
News
Novartis’ Kymriah fails to hit primary survival endpoint in late-stage trial
Phase III study was investigating treatment for B-cell non-Hodgkin lymphoma
EU nod for Bimzelx for moderate to severe plaque psoriasis
The approval is supported by three pivotal Phase III trials
Pfizer/BioNTech’s COVID-19 vaccine wins first full FDA approval
Biologics License Application approved to prevent COVID-19 in individuals 16 years of age and older
Kuvan approved for pregnant women with PKU in UK
NICE decision also extends treatment to people aged up to 22 years old
New BRCA-targeting drug could treat advanced prostate cancer
Talazoparib delayed disease progression in Phase II trial
NRG Therapeutics gains further funding from Parkinson’s UK
Investment will be used to support the development of disease modifying drugs to treat Parkinson’s disease
Valneva starts MHRA regulatory process for COVID-19 vaccine
VLA2001 is an inactivated, adjuvanted vaccine candidate
EC nod for Astellas, FibroGen’s roxadustat for chronic kidney disease
Phase III trial showed the drug achieved and maintained target Hb levels
UK approves monoclonal antibody treatment for COVID-19
Regeneron/Roche’s drug found to reduce hospitalisation
NICE recommends Novartis’ Rydapt for AdvSM treatment
Treatment provides therapeutic benefits to adults with the disease
US approval for Boehringer Ingelheim, Lilly’s heart failure drug Jardiance
Jardiance reduced risk of death or hospitalisation by 25% for adults with heart failure with reduced ejection fraction
BMS advances AI-designed drug candidate into development
Option is a collaboration between BMS and AI-driven pharmatech Exscientia
NICE’s health technology assessment methods and processes to be evaluated
Public consultation launches on proposed changes aiming to provide earlier access to new treatments
Accelerated FDA approval for GSK’s Jemperli
Indicated for the treatment of of dMMR recurrent or advanced solid tumours
